HES
MCID: HYP098
MIFTS: 63

Hypereosinophilic Syndrome (HES) malady

Categories: Genetic diseases, Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Hypereosinophilic Syndrome

About this section

Aliases & Descriptions for Hypereosinophilic Syndrome:

Name: Hypereosinophilic Syndrome 11 48 24 50 39 13 68
Eosinophilia 11 27 50 39 13 68
Hes 48 43
Disseminated Eosinophilic Collagen Disease 68
 
Hypereosinophilic Syndrome, Idiopathic 48
Idiopathic Hypereosinophilic Syndrome 68
Eosinophilic Leukocytosis 11
Eosinophilic Disorder 68

Classifications:



External Ids:

Disease Ontology11 DOID:999
ICD1030 D72.1
ICD9CM32 288.3

Summaries for Hypereosinophilic Syndrome

About this section
NIH Rare Diseases:48 Hypereosinophilic syndrome is a group of rare blood disorders characterized by increased levels of eosinophils (a type of white blood cell that plays a role in the human immune system) persisting for more than six months. the signs and symptoms are due to involvement of several internal organs and there is usually no evidence of parasites, allergy, or other known causes of an elevated eosinophil count. this condition largely occurs in males, typically at middle age. it usually presents with fever, weight loss, fatigue, and rash. an enlarged liver and spleen and liver is often present. the lungs, kidneys, heart, and nervous system can also be affected. last updated: 7/11/2011

MalaCards based summary: Hypereosinophilic Syndrome, also known as eosinophilia, is related to restrictive cardiomyopathy and lymphoblastic leukemia, and has symptoms including pruritus, myalgia and abdominal pain. An important gene associated with Hypereosinophilic Syndrome is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways are Osteoblast Signaling and IL-9 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types. The drugs interferon alfa-2b and recombinant interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and bone, and related mouse phenotypes are Decreased substrate adherent cell growth and Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435).

Wikipedia:71 The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil... more...

Related Diseases for Hypereosinophilic Syndrome

About this section

Diseases in the Hypereosinophilic Syndrome family:

Secondary Hypereosinophilic Syndrome Primary Hypereosinophilic Syndrome

Diseases related to Hypereosinophilic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 257)
idRelated DiseaseScoreTop Affiliating Genes
1restrictive cardiomyopathy30.2FIP1L1, IL5, PDGFRA, RNASE3
2lymphoblastic leukemia29.8CCL11, IL13, IL5
3hemophagocytic lymphohistiocytosis28.6ABL1, CSF2, IL2RA, IL3, KIT, PDGFRB
4eosinophilia-myalgia syndrome12.2
5myeloproliferative disorder with eosinophilia12.1
6primary hypereosinophilic syndrome12.1
7hypereosinophilic syndrome, idiopathic, resistant to imatinib12.1
8lymphocytic hypereosinophilic syndrome12.0
9secondary hypereosinophilic syndrome12.0
10endomyocardial fibrosis11.2
11episodic angioedema with eosinophilia10.9
12chronic eosinophilic leukemia10.7
13ganglioneuroma10.3FIP1L1, KIT, PDGFRA
14weaver syndrome10.3FIP1L1, PDGFRA, RNASE3
15dfnb110.3KIT, PDGFRA, PDGFRB
16olfactory nerve disease10.3FIP1L1, KIT, PDGFRA
17myeloid and lymphoid neoplasms associated with fgfr1 abnormalities10.3FGFR1, PDGFRA, PDGFRB
18global developmental delay-lung cysts-overgrowth-wilms tumor syndrome10.3PRG2, RNASE3
19leukemia10.3
20abdominal obesity-metabolic syndrome10.3FGFR1, PDGFRA, PDGFRB
21multifocal osteogenic sarcoma10.3KIT, PDGFRA, PDGFRB
22invasive mole10.2KIT, PDGFRA
23dupuytren contracture10.2FGFR1, KIT, PDGFRB
24lens-induced iridocyclitis10.2IL2RA, IL5, RNASE3
25autosomal dominant proximal renal tubular acidosis10.2FGFR1, FIP1L1, PDGFRA, PDGFRB
26latent syphilis10.2CCL11, IL5, RNASE3
27brown shrimp allergy10.2IL2RA, IL5, RNASE3
28cerebral primitive neuroectodermal tumor10.2CCL11, IL5, RNASE3
29orbital margin, hypoplasia of10.2FIP1L1, IFNA1, PDGFRA, PDGFRB
30oral leukoedema10.2FGFR1, KIT, PDGFRA
31infectious anterior uveitis10.2CXCL8, IL5, RNASE3
32thrombosis10.2
33dahlberg borer newcomer syndrome10.2IL13, IL5
34breast intracanalicular fibroadenoma10.2CXCL8, FGFR1, IL5
35astrocytoma10.2CCL17, IL5, RNASE3
36cutaneous fibrous histiocytoma10.2CCL11, IL2RA, IL5
37small intestine lymphoma10.2CXCL8, IL5, RNASE3
38dissociated nystagmus10.2CCL17, EPX, IL5
39middle lobe syndrome10.1CCL17, CXCL8, IL5
40temporomandibular ankylosis10.1FGFR1, FIP1L1, KIT, PDGFRA, PDGFRB
41lymphoma10.1
42thelaziasis10.1CCL11, IL13, IL5
43arteriosclerosis obliterans10.1ABL1, PDGFRB
44adenosarcoma10.1KIT, PDGFRA, PDGFRB
45spastic diplegia10.1CCL11, IL13, IL5
46isolated klippel-feil syndrome10.1IGHE, IL2RA, IL5
47peptidic growth factors deficiency10.1CCL11, IL5
48disordered steroidogenesis due to cytochrome p450 oxidoreductase10.1CCL11, IL13, IL5
49erythrocytosis, somatic10.1IFNA1, IL3, KIT, PDGFRA, PDGFRB
50actinic keratosis10.1IL13, IL5, RNASE3

Comorbidity relations with Hypereosinophilic Syndrome via Phenotypic Disease Network (PDN):


Deficiency AnemiaAcute Cystitis
BronchitisHeart Disease
Hypertension, EssentialIschemic Heart Disease

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome:



Diseases related to hypereosinophilic syndrome

Symptoms & Phenotypes for Hypereosinophilic Syndrome

About this section

UMLS symptoms related to Hypereosinophilic Syndrome:


pruritus, myalgia, abdominal pain, angina pectoris, chest pain, constipation, coughing, diarrhea, dyspepsia, edema, heartburn, icterus, nausea and vomiting, snoring, gastrointestinal gas

GenomeRNAi Phenotypes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00193-A-310.3ABL1, FGFR1, KIT
2GR00104-A-010.0CSF2, CXCL8, IL2RA, PDGFRB
3GR00381-A-19.9ABL1, FGFR1, KIT, PDGFRA, PDGFRB

MGI Mouse Phenotypes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.9ABL1, FGFR1, IL13, IL2RA, IL5, KIT
2MP:00053887.6ABL1, CCL11, CSF2, IL13, IL2RA, IL5
3MP:00053977.3ABL1, CCL11, CCL17, CSF2, EPX, FGFR1
4MP:00053877.2ABL1, CCL11, CCL17, CSF2, EPX, FGFR1

Drugs & Therapeutics for Hypereosinophilic Syndrome

About this section

Drugs for Hypereosinophilic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 289)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
BudesonideapprovedPhase 4, Phase 3, Phase 243251333-22-363006, 5281004
Synonyms:
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC-4697
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
B 7777
B7777_SIGMA
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Bidien
Bio-0010
Budecort Inhaler
Budenofalk
Budeson
Budesonide (JAN/USAN/INN)
Budesonide Easyhaler
Budesonide MMX
Budesonide [USAN:INN:BAN:JAN]
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
CPD000058337
Cortivent
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
EU-0100174
Entocort
Entocort EC
Entocort EC (TN)
Giona Easyhaler
HMS1569H17
HMS1921I22
HMS2094I13
HMS501H17
Horacort
 
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
LS-187734
LS-7235
Lopac0_000174
MAP-0010
MLS000028507
MLS001077323
MLS002207112
Micronyl
Miflonide
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Prestwick_840
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort Turbuhaler
Pulmicort turbuhaler
Respules
Rhinocort
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort alpha
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S-1320
S1286_Selleck
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
ST51039033
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Unit dose budesonide
ZINC03938751
ZINC04097286
budesonide
2
MontelukastapprovedPhase 4, Phase 3, Phase 1270158966-92-85281040
Synonyms:
(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
(R-(e))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1e)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
151767-02-1 (sodium)
158966-92-8
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
AC1NQXXW
Apxi toxin
BIDD:GT0394
Brondilat
Brondilat (TN)
C07482
C35H36ClNO3S
CHEBI:50730
CHEMBL787
CID5281040
 
D08229
DB00471
HMS2089D07
HSDB 7582
LS-173539
MK 0476
MK-0476
Montair
Montelukast
Montelukast (INN)
Montelukast [INN:BAN]
Montelukastum
Montélukast
Singulair
Singular
UNII-MHM278SD3E
montelukast
sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
{1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
3
Nitric OxideapprovedPhase 4, Phase 261710102-43-9145068
Synonyms:
(.)NO
(NO)(.)
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous Nitrate Vasodilator
Endothelium-Derived Nitric Oxide
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, Mononitrogen
Monoxide, Nitrogen
Monoxido de nitrogeno
Monoxyde d'azote
NITRIC-OXIDE
NO
NO(.)
Nitrate Vasodilator, Endogenous
Nitric Oxide, Endothelium Derived
 
Nitric Oxide, Endothelium-Derived
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
OHM 11771
Oxide, Nitric
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoff(ii)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, Endogenous Nitrate
[NO]
endothelium-derived relaxing factor
monoxido de nitrogeno
monoxyde d'azote
nitric oxide
nitrogen monooxide
nitrogen monoxide
nitrosyl
oxido de nitrogeno(II)
oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
4
Omalizumabapproved, investigationalPhase 4, Phase 2, Phase 1145242138-07-4
Synonyms:
242138-07-4
D05251
Ig gamma-1 chain C region
Omalizumab
 
Omalizumab (USAN/INN)
Omalizumab (genetical recombination)
Omalizumab (genetical recombination) (JAN)
Xolair
Xolair (TN)
5
Methylprednisoloneapproved, vet_approvedPhase 4, Phase 3119383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
6
Histamineapproved, investigationalPhase 4, Phase 3105075614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-(4-imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
4-imidazoleethylamine
5-Imidazoleethylamine
5-imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminoethylglyoxaline
beta-aminoethylimidazole
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
7
Lansoprazoleapproved, investigationalPhase 4, Phase 2, Phase 1218103577-45-33883
Synonyms:
103577-45-3
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
A 65006
A-65006
AB00052388
ABT-006
AC1L1GX8
AG 1749
AG-1749
Abbot Brand of Lansoprazole
Agopton
Almirall Brand of Lansoprazole
Amarin
Aprazol
BIDD:GT0006
BPBio1_001194
BRD-A49172652-001-05-7
BRN 4333393
BSPBio_001084
BSPBio_001830
Bamalite
Bio-0824
Biuret
Biuret Gr
Biuret Reagent
Biuret Reagent Solution
Blason
C058687
C16H14F3N3O2S
CAS-103577-45-3
CG-4801
CHEBI:6375
CHEMBL480
CID3883
CPD000058469
Compraz
D00355
DB00448
Dakar
DivK1c_000920
EU-0100709
FT-0082011
HMS1571G06
HMS1922M04
HMS2052F05
HMS2093M07
HMS502N22
HSDB 7204
Hoechst Brand of Lansoprazole
Hormona Brand of Lansoprazole
I06-0018
IDI1_000920
Ilsatec
KBio1_000920
KBio2_002060
KBio2_004628
KBio2_007196
KBio3_001330
KBioGR_001491
KBioSS_002060
Ketian
L 8533
L8533_SIGMA
LS-33080
Lancid
Lanfast
Lanproton
Lansopep
Lansophed
Lansoprazol
Lansoprazol [INN-Spanish]
Lansoprazole
Lansoprazole (JAN/USP/INN)
Lansoprazole [USAN:BAN:INN]
Lansoprazole [Usan:Ban:Inn]
Lansoprazolum
Lansoprazolum [INN-Latin]
Lansox
Lanston
 
Lanz
Lanzo
Lanzol
Lanzol-30
Lanzopral
Lanzor
Lanzul
Lapraz
Lasoprol
Lederle Brand of Lansoprazole
Limpidex
Linamarin
Lopac-L-8533
Lopac0_000709
MLS-0003247.0001
MLS000069705
MLS000759405
MLS001074170
Mesactol
MolPort-003-666-508
MolPort-006-394-760
Monolitum
NCGC00015615-01
NCGC00015615-02
NCGC00015615-03
NCGC00015615-06
NCGC00015615-11
NCGC00023826-03
NCGC00023826-04
NCGC00023826-05
NCGC00023826-06
NCGC00023826-07
NINDS_000920
Ogast
Ogastro
Opiren
Prestwick0_001072
Prestwick1_001072
Prestwick2_001072
Prestwick3_001072
PrevOnco
Prevacid
Prevacid (TN)
Prevacid I.V
Prevacid I.V.
Prevacid Iv
Prevacid SoluTab
Prevacid Solutab
Prevacid, Prevacid NapraPAC, Prevacid SoluTab, Lansoprazole
Prevpac
Prezal
Pro Ulco
Promeco
Promeco Brand of Lansoprazole
Promp
Prosogan
S1354_Selleck
SAM001246544
SMR000058469
SPBio_000488
SPBio_002992
SPECTRUM1503926
STK621169
Salvar Brand of Lansoprazole
Spectrum2_000444
Spectrum3_000295
Spectrum4_000856
Spectrum5_001521
Spectrum_001580
Suprecid
TAK 390MR
TAK-390MR
TAK390MR
TAP Brand of Lansoprazole
TL8000155
Takeda Brand of Lansoprazole
Takepron
Tecnobio Brand of Lansoprazole
UNII-0K5C5T2QPG
Ulpax
Vinas Brand of Lansoprazole
Wyeth Brand of Lansoprazole
Zoprol
Zoton
lansoprazole
lansoprazole sulphone
lanzoprazole
8
Prednisoloneapproved, vet_approvedPhase 4, Phase 3119350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
9
Ciclesonideapproved, investigationalPhase 474126544-47-6, 141845-82-1444033
Synonyms:
(R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
126544-47-6
141845-82-1
AC-1330
Alvesco
Alvesco (TN)
Alvesco HFA
B-9207-015
BTR-15
BTR-15K
BY-9010
BYK-20426
CID6918155
Ciclesonide
 
Ciclesonide (JAN/USAN/INN)
Ciclesonide [INN]
D01703
KS-1165
LS-186047
MolPort-005-940-705
NCGC00167972-01
Omnair
Omnaris
Omnaris HFA
Osonase
Osonide
RPR 251526
TBN-15
UNII-S59502J185
10
MentholapprovedPhase 426062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
11
VancomycinapprovedPhase 43321404-90-6441141, 14969
Synonyms:
(1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-Oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(2.2Sp,3.5sa,2.6sp)-O(4.2),C(3.4):c(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
1404-90-6
1404-93-9 (hydrochloride)
64685-75-2 (sulfate)
AC1L24VU
AC1L9AMI
AC1Q29OH
BIDD:GT0353
C06689
C66H75Cl2N9O24
CHEBI:28001
CHEMBL262777
CID14969
CID441141
CID5311496
CID6426898
CID6917992
D00212
DB00512
EINECS 215-772-6
HSDB 3262
LMPK14000004
 
LS-161387
Lopac0_001267
MolPort-001-794-649
NCGC00162383-02
Prestwick0_000497
Prestwick1_000497
Prestwick2_000497
SPBio_002314
UNII-6Q205EH1VU
VAN
VANCOMYCIN
Vancocin
Vancocin (TN)
Vancocin HCL
Vancomicina
Vancomicina [INN-Spanish]
Vancomycin
Vancomycin (USP)
Vancomycin HCL
Vancomycin [USAN:INN:BAN]
Vancomycine
Vancomycine [INN-French]
Vancomycinum
Vancomycinum [INN-Latin]
nchembio.350-comp1
12Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 110729
13Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113168
14Anti-Asthmatic AgentsPhase 4, Phase 3, Phase 2, Phase 13488
15glucocorticoidsPhase 4, Phase 3, Phase 2, Phase 15103
16Bronchodilator AgentsPhase 4, Phase 3, Phase 22965
17Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
18Leukotriene AntagonistsPhase 4, Phase 3, Phase 1293
19Autonomic AgentsPhase 4, Phase 3, Phase 210150
20
FluticasonePhase 4, Phase 3, Phase 264490566-53-3, 80474-14-262924, 22833648
Synonyms:
90566-53-3
AC-456
AC1NSJZT
Asmatil
Axotide
BIDD:GT0819
Brethal
C07815
CHEMBL1201396
CID5311101
Cultivate
Cutivate
D07981
Flixonase
Flixonase Nasal Spray
Flixotide
Flixotide Disk
 
Flixotide Disks
Flixotide Inhaler
Flonase
Flovent
Flovent Diskus
Flovent Rotadisk
Fluinol
Flunase
Flusonal
Fluspiral
Fluticaps
Fluticaps (TN)
Fluticasone (INN)
Fluticasonpropionat Allen
Flutide
Flutivate
MolPort-006-666-449
S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
fluticasone
21Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113180
22Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15806
23AntibodiesPhase 4, Phase 3, Phase 2, Phase 16394
24ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 16394
25Antibodies, MonoclonalPhase 4, Phase 3, Phase 2, Phase 14039
26Anti-Allergic AgentsPhase 4, Phase 3, Phase 2, Phase 11522
27Respiratory System AgentsPhase 4, Phase 3, Phase 2, Phase 14997
28Cromolyn SodiumPhase 417
29HormonesPhase 4, Phase 3, Phase 2, Phase 114415
30Endothelium-Dependent Relaxing FactorsPhase 4281
31Adrenergic beta-AgonistsPhase 4, Phase 21714
32Adrenergic beta-2 Receptor AgonistsPhase 4, Phase 2957
33Fluticasone Propionate, Salmeterol Xinafoate Drug CombinationPhase 4, Phase 2205
34AntioxidantsPhase 4, Phase 2, Phase 13050
35Vasodilator AgentsPhase 43543
36Anti-Ulcer AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 11842
37
DexlansoprazolePhase 4, Phase 2, Phase 1218138530-94-6, 103577-45-39578005
Synonyms:
138530-94-6
CHEMBL1201863
CID9578005
D08903
Dexlansoprazole (INN/USAN)
KS-1075
 
Kapidex
MolPort-002-885-834
T 168390
TAK 390
UNII-UYE4T5I70X
ZINC00599734
dexlansoprazole
38
Proton pump inhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 11123
Synonyms:
 
PPIs
39Adrenergic AgonistsPhase 4, Phase 23027
40AntacidsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 11842
41
Salmeterol xinafoatePhase 4, Phase 235994749-08-356801
Synonyms:
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
89365-50-4 (Parent)
94749-08-3
AC1L1LPS
Arial
Asmerole
Beglan
Betamican
Bio-0096
C25H37NO4.C11H8O3
CHEMBL1082607
CID56801
D00687
Dilamax
EU-0101100
GR 33343 G
GR 33343X xinafoate
 
GR-33343 G
Inaspir
LS-94516
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
S5068_SIGMA
SMR000875207
Salmetedur
Salmeterol 1-hydroxy-2-naphthoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN]
Serevent (TN)
Serevent Inhaler and Disks
Serevent diskus
UNII-6EW8Q962A5
Ultrabeta
salmeterol xinafoate
42AlbuterolPhase 4, Phase 2429
43Tocolytic AgentsPhase 4, Phase 2739
44Neurotransmitter AgentsPhase 4, Phase 3, Phase 218340
45Adrenergic AgentsPhase 4, Phase 25352
46Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 122062
47Neuroprotective AgentsPhase 41716
48Prednisolone acetatePhase 4, Phase 31193
49Methylprednisolone acetatePhase 4, Phase 31193
50Gastrointestinal AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 18402

Interventional clinical trials:

(show top 50)    (show all 267)
idNameStatusNCT IDPhase
1Efficacy and Safety of add-on Montelukast to Inhaled Budesonide in the Treatment of Nonasthmatic Eosinophilic BronchitisUnknown statusNCT01121016Phase 4
2Effect of Xolair on Airway HyperresponsivenessUnknown statusNCT00208234Phase 4
3Oral Cromolyn Sodium for the Treatment of Eosinophilic EsophagitisUnknown statusNCT02371941Phase 4
4Dietetic Versus Topical Steroids for Pediatric Eosinophilic EsophagitisUnknown statusNCT01846962Phase 4
5Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonistsCompletedNCT00670930Phase 4
6Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis SymptomsCompletedNCT00460538Phase 4
7The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic PneumoniaCompletedNCT00632554Phase 4
8Regulatory Lymphocytes in Patients Treated With Specific ImmunotherapyCompletedNCT01475188Phase 4
9Small Particle Steroids in Refractory AsthmaCompletedNCT01171365Phase 4
10Steroid Treatment for Hypereosinophilic SyndromeRecruitingNCT01524536Phase 4
11Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis PatientsRecruitingNCT02605213Phase 4
12Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMAActive, not recruitingNCT02546349Phase 4
13Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma PatientsActive, not recruitingNCT02654145Phase 4
14The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump InhibitorsTerminatedNCT01404832Phase 4
15Mepolizumab Treatment for Rhinovirus-induced Asthma ExacerbationsUnknown statusNCT01520051Phase 3
16A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic DisordersCompletedNCT00266578Phase 3
17Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma ControlCompletedNCT02281318Phase 3
18Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe AsthmaCompletedNCT01508936Phase 3
19A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01287039Phase 3
20A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic AsthmaCompletedNCT01285323Phase 3
21A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01270464Phase 3
22Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT01576367Phase 3
23Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT01302860Phase 3
24Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension PhaseCompletedNCT00991146Phase 3
25Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT00685373Phase 3
26Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells SyndromeCompletedNCT00465985Phase 3
27Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)CompletedNCT00647166Phase 3
28Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic EsophagitisCompletedNCT02434029Phase 3
29Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic EsophagitisCompletedNCT00635089Phase 3
30Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 YearsCompletedNCT00538434Phase 2, Phase 3
31Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantCompletedNCT01305200Phase 3
32Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
33The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic EsophagitisCompletedNCT00728481Phase 2, Phase 3
34Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00369317Phase 3
35Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006363Phase 3
36Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)RecruitingNCT02836496Phase 3
37Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.RecruitingNCT02563067Phase 3
38Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.RecruitingNCT02555683Phase 3
39A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic AsthmaRecruitingNCT03052725Phase 3
40Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma PatientsRecruitingNCT02555371Phase 3
41SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet StudyRecruitingNCT02778867Phase 2, Phase 3
42Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed GlucocorticoidsRecruitingNCT02610816Phase 2, Phase 3
43An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)RecruitingNCT02736409Phase 3
44A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is AchievedRecruitingNCT02605837Phase 3
45Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic EsophagitisRecruitingNCT02493335Phase 3
46Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY StudyActive, not recruitingNCT02594332Phase 3
47Treatment of Asymptomatic Toxocariasis With Albendazole in ChildrenActive, not recruitingNCT00755560Phase 3
48Eosinophilic Esophagitis Treatment: Montelukast vs FluticasoneActive, not recruitingNCT01702701Phase 3
49Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic AsthmaEnrolling by invitationNCT02559791Phase 2, Phase 3
50Trial of Ketotifen in Children and AdolescentsNot yet recruitingNCT02484248Phase 3

Search NIH Clinical Center for Hypereosinophilic Syndrome

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: eosinophilia

Genetic Tests for Hypereosinophilic Syndrome

About this section

Genetic tests related to Hypereosinophilic Syndrome:

id Genetic test Affiliating Genes
1 Eosinophilia27
2 Hypereosinophilic Syndrome24 PDGFRA

Anatomical Context for Hypereosinophilic Syndrome

About this section

MalaCards organs/tissues related to Hypereosinophilic Syndrome:

36
Heart, Liver, Bone, Bone marrow, T cells, Lung, Spleen

Publications for Hypereosinophilic Syndrome

About this section

Articles related to Hypereosinophilic Syndrome:

(show top 50)    (show all 637)
idTitleAuthorsYear
1
Hypereosinophilic syndrome. (28052805)
2017
2
Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes. (28337408)
2017
3
Idiopathic hypereosinophilic syndrome manifesting with eosinophilic cholecystitis and recurrent gastroenteritis. (28378039)
2017
4
Idiopathic hypereosinophilic syndrome presenting with hepatitis and achalasia. (27294613)
2016
5
Hypereosinophilic syndrome: cardiac diagnosis and management. (26567231)
2016
6
Characterization of left atrial dysfunction in hypereosinophilic syndrome - Insights from the Motion analysis of the heart and great vessels by three-dimensional speckle tracking echocardiography in pathological cases (MAGYAR-Path) Study. (27118091)
2016
7
Idiopathic hypereosinophilic syndrome resulting in distal aortic thromboembolism in a dog. (27723953)
2016
8
Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. (26797802)
2016
9
Hypereosinophilic Syndrome: A Case of Fatal LAPffler Endocarditis. (26904305)
2016
10
Acute Paracoccidioidomycosis Due to Paracoccidioides brasiliensis S1 Mimicking Hypereosinophilic Syndrome with Massive Splenomegaly: Diagnostic Challenge. (27054891)
2016
11
Generalized Recalcitrant Pruritus as the Presenting Manifestation of Hypereosinophilic Syndrome. (26826106)
2016
12
Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. (26702067)
2016
13
Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: Eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome? (27915050)
2016
14
Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome. (27231866)
2016
15
Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. (27803915)
2016
16
IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series. (28005278)
2016
17
Idiopathic hypereosinophilic syndrome presenting as angina pectoris: A case report. (27521535)
2016
18
Frequency of abnormal T-cells in hypereosinophilic syndrome and hypereosinophilia of undetermined significance- Extended follow-up. (27267517)
2016
19
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. (27887955)
2016
20
Eosinophilic pleural effusion as a manifestation of idiopathic hypereosinophilic syndrome. (27185511)
2016
21
Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. (27125206)
2016
22
Rheumatoid arthritis heralded by the hypereosinophilic syndrome. (27554003)
2016
23
Gastrointestinal and Hepatic Involvement in Hypereosinophilic Syndrome. (27733964)
2016
24
Paediatric presentation of cardiac involvement in hypereosinophilic syndrome. (27329338)
2016
25
Pulmonary embolism, deep vein thrombosis and recurrent bone cysts in a patient with hypereosinophilic syndrome. (26780165)
2016
26
Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman. (27158718)
2016
27
Cardiac involvement in hypereosinophilic syndrome. (26853257)
2016
28
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. (27174585)
2016
29
A Possible Case of Hepatitis due to Hypereosinophilic Syndrome. (27250051)
2016
30
Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis. (27911676)
2016
31
Idiopathic Hypereosinophilic Syndrome Associated with Endomyocardial Fibrosis, Intracardiac Thrombi, Pulmonary and Skin Infiltration: A Case Report. (27617583)
2016
32
Lymphocytic variant of Hypereosinophilic syndrome with deep vein thrombosis. (27728750)
2016
33
Idiopathic hypereosinophilic syndrome. (27728301)
2016
34
Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: A case report and literature review. (27583887)
2016
35
Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome. (27681117)
2016
36
Very early stage left ventricular endocardial dysfunction of patients with hypereosinophilic syndrome. (27240601)
2016
37
Hypereosinophilic Syndrome: Hacettepe Experience. (27548336)
2016
38
Biventricular thrombus in hypereosinophilic syndrome presenting with shortness of breath. (27896330)
2016
39
Superficial femoral artery thromosis secondary to hypereosinophilic syndrome. (27728032)
2016
40
WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM. (26182612)
2015
41
A Rare Case of Aortic Valve Thrombosis in Patient with Idiopathic Hypereosinophilic Syndrome. (26435854)
2015
42
Multiple cerebral infarctions in a patient with hypereosinophilic syndrome with LAPffler endocarditis: a case report. (25786753)
2015
43
CD30+ clonal T-cell lymphoid proliferation of the skin in a patient with hypereosinophilic syndrome. (25421540)
2015
44
Imatinib Treatment in PDGFRA-Negative Childhood Hypereosinophilic Syndrome. (26257279)
2015
45
MRI-based Evidence for Myocardial Involvement in Women with Hypereosinophilic Syndrome. (25740233)
2015
46
Comparison of two leukocytapheresis protocols in a case of idiopathic hypereosinophilic syndrome. (26463664)
2015
47
Pyoderma gangrenosum in association with microscopic colitis, idiopathic hypereosinophilic syndrome, selective IgE deficiency and diabetes mellitus. (25704069)
2015
48
Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system. (25843450)
2015
49
Treatment-refractory hypereosinophilic syndrome responding to fludarabine in a 12-year-old boy. (25549807)
2015
50
Hypereosinophilic Syndrome. (26475367)
2015

Variations for Hypereosinophilic Syndrome

About this section

Expression for genes affiliated with Hypereosinophilic Syndrome

About this section
Search GEO for disease gene expression data for Hypereosinophilic Syndrome.

Pathways for genes affiliated with Hypereosinophilic Syndrome

About this section

Pathways related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 44)
idSuper pathwaysScoreTop Affiliating Genes
110.1PDGFRA, PDGFRB
29.9IL13, IL5
39.8FGFR1, PDGFRA, PDGFRB
4
Show member pathways
9.8FGFR1, PDGFRA, PDGFRB
5
Show member pathways
9.7FGFR1, KIT, PDGFRB
69.7CSF2, IL3, IL5
79.6FGFR1, KIT, PDGFRA, PDGFRB
89.4CSF2, IL2RA, PDGFRA, PDGFRB
9
Show member pathways
9.4CXCL8, KIT, PDGFRA, PDGFRB
10
Show member pathways
9.4CSF2, IL2RA, IL3, IL5
119.4CSF2, CXCL8, IL13
129.3CSF2, IL13, IL3, IL5
139.3IL13, IL2RA, IL5, KIT
14
Show member pathways
9.3ABL1, KIT, PDGFRA, PDGFRB
159.2CSF2, CXCL8, IL13, IL5
169.2CCL11, CCL17, IGHE, IL5
179.1CSF2, IL2RA, IL3, IL5, KIT
189.1CSF2, IL2RA, IL3, IL5, KIT
199.1IFNA1, IL2RA, IL3
209.0ABL1, FGFR1, KIT, PDGFRA, PDGFRB
21
Show member pathways
9.0ABL1, FGFR1, KIT, PDGFRA, PDGFRB
22
Show member pathways
9.0CSF2, CXCL8, IL2RA, IL3, IL5
23
Show member pathways
9.0FGFR1, IL2RA, IL3, KIT, PDGFRA, PDGFRB
249.0CCL11, CCL17, IL13, IL2RA, IL5
258.9CCL11, CXCL8, IGHE, IL13
268.9CCL11, CSF2, CXCL8, IL13, IL5
27
Show member pathways
8.9FGFR1, IL13, IL2RA, IL5, PDGFRA, PDGFRB
28
Show member pathways
8.8CSF2, IGHE, IL13, IL3, IL5
298.7ABL1, CXCL8, FGFR1, KIT, PDGFRA, PDGFRB
30
Show member pathways
8.6CCL11, CCL17, CSF2, CXCL8, IL13, IL5
31
Show member pathways
8.5FGFR1, IL2RA, IL3, KIT, PDGFRA, PDGFRB
32
Show member pathways
8.4CXCL8, IFNA1, IL13, IL3, IL5
338.3CCL11, CCL17, CSF2, CXCL8, IL13, IL3
348.2FGFR1, IFNA1, IL2RA, IL3, KIT, PDGFRA
35
Show member pathways
8.2CSF2, IFNA1, IL13, IL2RA, IL3, IL5
36
Show member pathways
8.0ABL1, CSF2, FGFR1, IL2RA, IL3, IL5
37
Show member pathways
7.1CCL11, CCL17, CSF2, CXCL8, FGFR1, IL13
38
Show member pathways
7.1CCL11, CCL17, CSF2, CXCL8, FGFR1, IL13
39
Show member pathways
6.6CCL11, CCL17, CXCL8, FGFR1, IFNA1, IL13
40
Show member pathways
6.3CCL11, CCL17, CSF2, CXCL8, FGFR1, IFNA1
41
Show member pathways
6.2ABL1, CCL11, CXCL8, EPX, IFNA1, IL13
42
Show member pathways
6.1ABL1, CCL11, CCL17, CSF2, CXCL8, FGFR1
43
Show member pathways
6.1CCL11, CSF2, CXCL8, FGFR1, IFNA1, IGHE
44
Show member pathways
4.6ABL1, CCL11, CSF2, CXCL8, EPX, FGFR1

GO Terms for genes affiliated with Hypereosinophilic Syndrome

About this section

Cellular components related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:00098979.6IGHE, IL13, IL2RA, KIT, PDGFRA
2extracellular spaceGO:00056156.7CCL11, CCL17, CSF2, CXCL8, EPX, IFNA1
3extracellular regionGO:00055766.5CCL11, CCL17, CSF2, CXCL8, EPX, FGFR1

Biological processes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 40)
idNameGO IDScoreTop Affiliating Genes
1cardiac myofibril assemblyGO:005500310.9PDGFRA, PDGFRB
2metanephric glomerular capillary formationGO:007227710.8PDGFRA, PDGFRB
3negative regulation of platelet-derived growth factor receptor-beta signaling pathwayGO:200058710.8PDGFRA, PDGFRB
4positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayGO:003809110.8PDGFRA, PDGFRB
5mast cell chemotaxisGO:000255110.7CCL11, KIT
6positive regulation of podosome assemblyGO:007180310.7CSF2, IL5
7cell chemotaxisGO:006032610.6KIT, PDGFRA, PDGFRB
8defense response to nematodeGO:000221510.5EPX, PRG2
9negative regulation of interleukin-10 productionGO:003269310.5EPX, PRG2
10positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.5KIT, PDGFRA, PDGFRB
11platelet-derived growth factor receptor-beta signaling pathwayGO:003579110.5ABL1, PDGFRB
12positive regulation of MAP kinase activityGO:004340610.5FGFR1, KIT, PDGFRB
13positive regulation of DNA replicationGO:004574010.5CSF2, IL3, PDGFRA
14positive regulation of tyrosine phosphorylation of STAT proteinGO:004253110.3CSF2, IL3, KIT
15positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.3CSF2, IL3, KIT
16phosphatidylinositol phosphorylationGO:004685410.3FGFR1, KIT, PDGFRA, PDGFRB
17phosphatidylinositol-mediated signalingGO:004801510.3FGFR1, KIT, PDGFRA, PDGFRB
18platelet-derived growth factor receptor signaling pathwayGO:004800810.3ABL1, PDGFRA, PDGFRB
19cellular response to interleukin-1GO:007134710.3CCL11, CCL17, CXCL8
20chemokine-mediated signaling pathwayGO:007009810.3CCL11, CCL17, CXCL8
21positive regulation of cell migrationGO:003033510.3CCL11, KIT, PDGFRA, PDGFRB
22neutrophil chemotaxisGO:003059310.3CCL11, CCL17, CXCL8
23positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.3FGFR1, KIT, PDGFRA, PDGFRB
24positive regulation of phospholipase C activityGO:001086310.3FGFR1, KIT, PDGFRA, PDGFRB
25positive regulation of peptidyl-tyrosine phosphorylationGO:005073110.2ABL1, IL3, IL5
26response to fluid shear stressGO:003440510.1CSF2, PDGFRB
27retina vasculature development in camera-type eyeGO:006129810.1PDGFRA, PDGFRB
28chemotaxisGO:00069359.9CCL11, CCL17, CXCL8, PDGFRA, PDGFRB
29regulation of phosphatidylinositol 3-kinase signalingGO:00140669.9FGFR1, KIT, PDGFRA, PDGFRB
30protein autophosphorylationGO:00467779.7ABL1, FGFR1, KIT, PDGFRA, PDGFRB
31positive regulation of ERK1 and ERK2 cascadeGO:00703749.7ABL1, CCL11, CCL17, PDGFRA, PDGFRB
32cytokine-mediated signaling pathwayGO:00192219.7IFNA1, IL3, IL5, KIT
33regulation of cell proliferationGO:00421279.6ABL1, CSF2, FGFR1, KIT
34positive regulation of cell proliferationGO:00082849.5CSF2, FGFR1, IL3, IL5, KIT, PDGFRA
35protein phosphorylationGO:00064689.4ABL1, CCL11, FGFR1, KIT, PDGFRA, PDGFRB
36MAPK cascadeGO:00001659.2CSF2, FGFR1, IL2RA, IL3, IL5, KIT
37inflammatory responseGO:00069549.1CCL11, CCL17, CXCL8, IL13, IL2RA, IL5
38peptidyl-tyrosine phosphorylationGO:00181089.0ABL1, CSF2, FGFR1, IL3, IL5, KIT
39positive regulation of GTPase activityGO:00435478.6CCL11, CCL17, CSF2, FGFR1, IL2RA, IL3
40immune responseGO:00069557.8CCL11, CCL17, CSF2, CXCL8, IGHE, IL13

Molecular functions related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1platelet-derived growth factor bindingGO:004840710.8PDGFRA, PDGFRB
2platelet-derived growth factor receptor bindingGO:000516110.8PDGFRA, PDGFRB
3phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:004693410.2FGFR1, KIT, PDGFRA, PDGFRB
4chemokine activityGO:000800910.2CCL11, CCL17, CXCL8
5vascular endothelial growth factor bindingGO:003808510.1PDGFRA, PDGFRB
6protein kinase activityGO:00046729.7ABL1, FGFR1, KIT, PDGFRA, PDGFRB
7transmembrane receptor protein tyrosine kinase activityGO:00047149.6FGFR1, KIT, PDGFRA, PDGFRB
8Ras guanyl-nucleotide exchange factor activityGO:00050888.9CSF2, FGFR1, IL2RA, IL3, IL5, KIT
9protein tyrosine kinase activityGO:00047138.8ABL1, CSF2, FGFR1, IL3, IL5, KIT
10cytokine activityGO:00051258.2CCL11, CCL17, CSF2, CXCL8, IFNA1, IL13

Sources for Hypereosinophilic Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet